These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 18547271)
1. Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease. Korolainen MA; Pirttilä T Acta Neurol Scand; 2009 Jan; 119(1):32-8. PubMed ID: 18547271 [TBL] [Abstract][Full Text] [Related]
2. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. Ahmed N; Ahmed U; Thornalley PJ; Hager K; Fleischer G; Münch G J Neurochem; 2005 Jan; 92(2):255-63. PubMed ID: 15663474 [TBL] [Abstract][Full Text] [Related]
3. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606 [TBL] [Abstract][Full Text] [Related]
4. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Aldred S; Bennett S; Mecocci P Clin Biochem; 2010 Feb; 43(3):267-71. PubMed ID: 19733555 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
7. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. Abe T; Tohgi H; Isobe C; Murata T; Sato C J Neurosci Res; 2002 Nov; 70(3):447-50. PubMed ID: 12391605 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer's disease. Ryberg H; Söderling AS; Davidsson P; Blennow K; Caidahl K; Persson LI Neurochem Int; 2004 Jul; 45(1):57-62. PubMed ID: 15082222 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls. Peskind ER; Leverenz J; Farlow MR; Ito RK; Provow SA; Siegel RS; Cleveland M; Morgan CH; Pandian MR; Corbin S; Nochlin D; Schellenberg GD; Raskind MA; Wagner SL Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):201-6. PubMed ID: 9437437 [TBL] [Abstract][Full Text] [Related]
10. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910 [TBL] [Abstract][Full Text] [Related]
12. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966 [TBL] [Abstract][Full Text] [Related]